To succeed in an increasingly competitive marketplace, pharmaceutical companies must have a strong Environmental, Social and Governance (ESG) strategy in place. Not only does this create value by supporting top-line growth and reducing costs, but it also encourages continued investment from partners seeking to uphold their brand reputation through assurance of supply. Critically, by both safeguarding patient access to essential medicines and delivering on the needs of external stakeholders, strong ESG initiatives promise enhanced business performance that translates to countless benefits for everyone involved.

A strong indication that a company is executing its ESG strategy is through inclusion in the Dow Jones Sustainabaility Index (DJSI), a widely used frame-work for evaluating the sustainability performance of thousands of publicly traded companies. Because only the top 10 percent of each industry endure the sustainability best-in-class selection process, being listed in the DJSI bolsters a company’s reputation and future prospects, making it a more attractive prospect to business partners, financial analysts / investors, and broader public stakeholders alike.

AbbVie’s Contract Manufacturing Organization (CMO) has been included as part of the company’s DJSI rankings since 2013, where it is a consistent biotech industry leader. Moreover, when AbbVie’s score is broken down into its component parts, we excel for several key performance indicators, many of which are closely aligned with our commitment to assurance of supply. The value of our DJSI ranking is globally recognized by our partners, who know they can rely on AbbVie CMO for quality products and services, a robust supply chain, and expert technical support, delivered with laser focus on world class Environmental, Health and Safety (EHS) performance, as well as continuous improvement.

Download the full case study to read more